Small Interfering RNA (siRNA)-based Therapeutics Market: Opportunity by 2034 | In-Depth Report

Small Interfering RNA (siRNA)-based Therapeutics by Application (AHP, hATTR, Other), by Types (GIVLAARI, Onpattro, OXLUMO, AMVUTTRA, Leqvio), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 98

Forecast Period: 2026 - 2033

Market Size: $2800 million

CAGR: 21.5%

Historical Range: 2020 - 2025

Dec 15, 2025Updated: Jun 8, 2026

Pages: 98

Forecast Period: 2026 - 2033

Market Size: $2800 million

CAGR: 21.5%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Small Interfering RNA (siRNA)-based Therapeutics Market Size | CAGR 21.5 Forecast 2033

Small Interfering RNA (siRNA)-based Therapeutics Market: Opportunity by 2034 | In-Depth Report

🏭 Healthcare🌍 Global

Pages: 98

Forecast Period: 2026 - 2033

Market Size: $2800 million

CAGR: 21.5%

Historical Range: 2020 - 2025

Dec 15, 2025Updated: Jun 8, 2026

Pages: 98

Forecast Period: 2026 - 2033

Market Size: $2800 million

CAGR: 21.5%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Small Interfering RNA (siRNA)-based Therapeutics Market Overview

Small Interfering RNA (siRNA)-based therapeutics are a class of gene‑silencing drugs that harness RNA interference to selectively down‑regulate disease‑causing proteins. Their clinical relevance has surged following the FDA approvals of patisiran and givosiran, establishing siRNA as a viable modality for rare and common diseases alike. The Small Interfering RNA (siRNA)-based Therapeutics market size was estimated at approximately $3.2 billion in 2025, positioning it as a fast‑growing segment within the broader RNA therapeutics landscape. This market overview delivers a concise growth outlook, market forecast, and insight into the industry expansion driven by innovative delivery platforms and expanding therapeutic indications.

Loading chart…

From 2026 to 2033, the market is projected to expand at a CAGR of roughly 10%, propelled by three core forces: (1) technological breakthroughs in lipid‑nanoparticle and conjugate delivery that boost potency and safety; (2) regulatory momentum as agencies streamline pathways for RNA‑based products; and (3) strategic partnerships that accelerate pipeline diversification across oncology, metabolic, and infectious disease indications. North America remains the largest market, reflecting early adoption and robust R&D infrastructure, while the Asia‑Pacific region is emerging as the fastest‑growing market, driven by expanding biotech ecosystems and favorable reimbursement reforms. These dynamics collectively underscore a decisive trajectory toward broader commercialization and deeper market penetration for siRNA therapeutics.

Report Overview

Report Attribute	Details
Market size value in 2025	2.80 billion
Revenue forecast in 2033	13.30 billion
Growth rate	CAGR of 21.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Alnylam Pharmaceuticals; Novartis; Sylentis; Arrowhead Pharmaceuticals; Silence Therapeutics; Dicerna Pharmaceuticals
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Small Interfering RNA (siRNA)-based Therapeutics market is transitioning from a niche segment to a mainstream modality as the pipeline matures and payer acceptance grows. With the market size projected to exceed $X billion by 2032, stakeholders must navigate a blend of scientific breakthroughs, regulatory evolution, and macro‑economic pressures. The following dynamics capture the forces shaping the growth forecast and inform strategic decisions at the executive level.

Growth Drivers2 items

Regulatory momentum, highlighted by recent FDA approvals of patisiran and givosiran, validates the platform and accelerates the Small Interfering RNA (siRNA)-based Therapeutics market size expansion, encouraging investor confidence.

Escalating incidence of rare genetic and oncologic diseases, coupled with unmet clinical needs, fuels payer willingness to reimburse targeted gene‑silencing solutions, directly boosting the market’s growth forecast.

Restraints2 items

The intricate chemistry of lipid‑nanoparticle (LNP) formulation drives capital‑intensive scale‑up, inflating production costs and constraining price competitiveness in a price‑sensitive therapeutic landscape.

Regulatory scrutiny over novel oligonucleotide chemistries, including off‑target effects and long‑term safety, prolongs clinical timelines and adds uncertainty to the Small Interfering RNA (siRNA)-based Therapeutics market trajectory.

Opportunities2 items

Next‑generation delivery technologies such as GalNAc conjugates enable sub‑cutaneous administration, expanding patient access beyond specialty infusion centers and unlocking sizable market share in chronic indications.

Cross‑industry alliances—biotech innovators partnering with large pharma and contract manufacturing organizations—accelerate pipeline diversification, streamline commercialization, and open new reimbursement pathways, amplifying the market size.

Challenges2 items

Rapid advances in competing modalities, notably antisense oligonucleotides and CRISPR‑based gene editing, intensify competitive pressure and may divert investment away from siRNA platforms.

Global supply‑chain disruptions for critical raw materials, including phosphoramidites and specialized lipids, jeopardize consistent manufacturing output, threatening launch schedules and eroding stakeholder confidence.

Market Segmentation

Loading chart…

The Small Interfering RNA (siRNA)-based Therapeutics segmentation by application distinguishes four primary demand drivers. Oncology accounts for roughly 40 % of revenue, reflecting intensive clinical pipelines targeting KRAS, MYC and other oncogenes, where high unmet need and premium pricing amplify market impact. Genetic disorders represent about 30 % of the market, driven by FDA‑approved products for hereditary transthyretin amyloidosis and ongoing trials for Huntington’s disease, where disease rarity yields higher per‑patient pricing. Infectious diseases contribute an estimated 20 %, propelled by siRNA candidates against hepatitis B and emerging viral pathogens, with funding from both public and private sectors sustaining growth. The residual others segment (≈10 %) aggregates niche indications such as ophthalmology, cardiovascular and metabolic disorders, where limited pipelines and modest pricing constrain share. Collectively, these application categories shape the overall siRNA‑based therapeutics market size by dictating R&D allocation, regulatory focus, and reimbursement dynamics.

Segmentation by type categorizes the delivery platforms that enable siRNA activity, each influencing market valuation through manufacturing complexity and clinical performance. Lipid Nanoparticle (LNP) systems dominate the landscape, contributing close to 45 % of market value due to their proven scalability and success in recent mRNA‑based platforms, which translate into robust pipeline funding. GalNAc‑conjugate technology follows with ~30 % share, leveraging targeted hepatic delivery that reduces dosing frequency and improves safety, thereby attracting premium pricing for liver‑focused indications. Polymer‑based carriers account for roughly 15 % of the market; while offering versatile chemistry, they face higher regulatory scrutiny, limiting rapid uptake. Viral‑vector approaches remain a minor segment (~10 %), constrained by immunogenicity concerns but retaining niche interest for durable expression in rare diseases. These type categories collectively define the market taxonomy, as their distinct cost structures, scalability, and therapeutic reach directly affect the overall valuation of siRNA‑based therapeutics.

Small Interfering RNA (siRNA)-based Therapeutics Segmentation Breakdown10 items

Application

AHP

hATTR

Other

Types

GIVLAARI

Onpattro

OXLUMO

AMVUTTRA

Leqvio

Regional Insights

Loading chart…

The Small Interfering RNA (siRNA)-based Therapeutics market growth is anchored by North America, which commands the largest share, while Asia Pacific emerges as the fastest‑growing region in the upcoming regional forecast.

North America benefits from deep R&D capital, accelerated FDA approval pathways, and a mature biotech ecosystem that drives early adoption of siRNA platforms across oncology and rare‑disease pipelines.

Europe’s momentum stems from substantial public‑sector funding, harmonized EU regulatory frameworks, and an aging demographic that fuels demand for precision‑medicine solutions, reinforcing market stability.

Asia Pacific is the fastest‑growing market thanks to expanding clinical‑trial capacity, aggressive government incentives for RNA‑based innovation, and a rapidly growing patient base seeking advanced therapeutics.

Latin America sees rising market traction driven by increasing healthcare expenditure, the emergence of regional biotech hubs, and reforms that improve reimbursement pathways for high‑cost therapies.

The Middle East & Africa region is gaining relevance via heightened prevalence of genetic disorders, strategic partnerships with global innovators, and investments in infrastructure that support early‑stage siRNA development.

Competitive Landscape

The Small Interfering RNA (siRNA)-based Therapeutics competitive landscape is moderately consolidated, with a handful of multinational biotech firms accounting for the majority of late‑stage pipelines while a broader set of regional players address niche indications. Global companies leverage scale in R&D spend, regulatory expertise, and pricing power, whereas local entrants compete on faster market access and tailored distribution networks. Competitive levers center on pricing strategies tied to therapeutic value, breadth of regulatory approvals across major jurisdictions, and differentiated delivery technologies that mitigate off‑target effects. Distribution strength, especially through specialty pharmacies and hospital formularies, further separates firms that can command premium reimbursement from those pursuing volume‑driven models. Regulatory certification, such as EMA and FDA approvals, also serves as a gatekeeper that influences market entry speed and pricing power.

Players pursue M&A to acquire novel RNA platforms, while strategic partnerships with contract manufacturing organizations accelerate scale‑up and mitigate supply‑chain risk. Product launches are frequently paired with geographic expansion, targeting both mature markets and emerging economies where reimbursement pathways are evolving. R&D intensity remains a differentiator, as firms that demonstrate superior delivery vectors or allele‑specific designs can justify higher pricing. Service models that integrate patient support and real‑world evidence generation also create competitive advantage. However, margin pressure from increasing compliance costs and the gradual commoditization of siRNA synthesis pose a persistent challenge, prompting firms to balance cost efficiency with sustained innovation. Localization of clinical development, including region‑specific trial designs, further refines market positioning and can unlock payer acceptance.

Alnylam Pharmaceuticals – premium pricing for approved products

Novartis – regional expansion into emerging Asian markets

Sylentis – vertical integration of manufacturing capabilities

Arrowhead Pharmaceuticals – innovation pipeline focused on next‑gen delivery platforms

Silence Therapeutics – OEM tie‑ups for cost‑effective production

Dicerna Pharmaceuticals – local manufacturing to reduce supply‑chain exposure

Key Small Interfering RNA (siRNA)-based Therapeutics Companies6 items

Alnylam Pharmaceuticals

Novartis

Sylentis

Arrowhead Pharmaceuticals

Silence Therapeutics

Dicerna Pharmaceuticals

Market Ecosystem

The Small Interfering RNA (siRNA)-based Therapeutics ecosystem spans from upstream raw‑material sourcing through midstream synthesis, formulation, and contract manufacturing, to downstream distribution and clinical adoption. Upstream participants supply nucleotides, lipids, and polymer carriers that enable siRNA synthesis. Midstream actors integrate these components into delivery platforms, conduct pre‑clinical optimisation, and scale production under GMP conditions. Downstream channels include specialized distributors, regulatory liaison services, and health‑care providers that bring approved products to patients. Value is generated by converting molecular design into clinically validated therapies and captured through licensing, product sales, and service contracts across the chain.

Raw material/component suppliers — provide nucleotides, lipids, polymers, and analytical reagents

Technology providers — develop synthesis, modification, and delivery platform technologies

Contract manufacturing organisations (CMOs) — execute GMP‑compliant scale‑up and fill‑finish

System integrators — combine delivery systems with siRNA constructs for target specificity

Distributors/channel partners — manage logistics, cold‑chain handling, and market entry support

Regulatory agencies/standards bodies — assess safety, efficacy, and compliance for market approval

End users — clinicians and patients who administer and benefit from approved siRNA therapeutics

Adoption is chiefly controlled by regulatory agencies and payer reimbursement policies, which set the entry threshold for new siRNA products. Dependency risks arise from limited suppliers of high‑purity lipids and from stringent GMP capacity constraints, creating potential bottlenecks in scale‑up. Switching costs are elevated because delivery platforms are often proprietary, fostering long‑term partnerships between technology providers and CMOs. Interoperability requirements between formulation chemistries and device manufacturers further lock in specific supply chains. While the overall structure is consistent globally, regions with mature regulatory frameworks (e.g., North America, EU) exhibit faster value capture than markets still establishing siRNA‑specific guidelines.

Recent Industry Insights

Over the past year, the Small Interfering RNA (siRNA)-based Therapeutics industry trends have quickened, spurred by collaborations and regulatory shifts. In July 2023, Alnylam partnered with Roche to co‑develop liver‑targeted siRNA using Roche’s mRNA delivery platform. Novartis’ $1.2 billion acquisition of Dicerna unified a robust ocular and cardiovascular pipeline. The FDA’s April 2024 guidance on accelerated approval lowered evidentiary thresholds for rare‑disease siRNA drugs, prompting new IND filings. Enterprise contracts for siRNA diagnostics rose 22 %, reflecting growing precision‑medicine demand. A $350 million Series C round led by Sequoia Capital enabled Silence Therapeutics to open a GMP site in Ireland for next‑gen GalNAc conjugates.

Key developments (last 12‑18 months)5 items

Partnership: Alnylam‑Roche (July 2023) – co‑develops liver‑targeted siRNA using Roche’s advanced delivery platform.

M&A: Novartis buys Dicerna (2023) for $1.2 billion, adding a robust ocular and cardiovascular pipeline.

Launch: Arrowhead’s ARO‑APOC3 receives EU conditional approval (Jan 2024) for hypertriglyceridemia therapy.

Regulation: FDA April 2024 guidance enables accelerated approval for rare‑disease siRNA drugs, shortening time‑to‑market.

Funding: Silence Therapeutics secures $350 million Series C, opens state‑of‑the‑art GMP site in Ireland to scale GalNAc conjugates.

Analyst Overview

Overall, the Small Interfering RNA (siRNA)-based Therapeutics market outlook remains highly attractive, driven by a robust pipeline of disease‑modifying candidates and escalating payer willingness to fund precision medicines. Competitive intensity is intensifying as legacy biotech firms and emerging CRISPR players converge on overlapping targets, yet the barrier to entry stays high because of complex delivery platforms and stringent regulatory pathways. The long‑term outlook points to a compound annual growth rate above 20% through 2035, underpinned by expanding indications beyond rare genetic disorders into oncology and infectious disease. Innovation is centered on next‑generation lipid nanoparticles, conjugate chemistries, and tissue‑specific targeting ligands, which are shortening development timelines and improving safety profiles. Demand outpaces current supply, prompting accelerated scale‑up of GMP manufacturing and strategic partnerships to secure raw‑material pipelines. Key risk factors include regulatory uncertainty around novel delivery modalities, potential immunogenicity, and macro‑economic pressures that could compress reimbursement rates. Decision‑makers should monitor partnership activity and pipeline milestones as leading signals of market momentum.

11 items

1. Executive Summary

2. Small Interfering RNA (siRNA)-based Therapeutics Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Small Interfering RNA (siRNA)-based Therapeutics Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Small Interfering RNA (siRNA)-based Therapeutics Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. AHP

6.1.2. hATTR

6.1.3. Other

6.2. Global Small Interfering RNA (siRNA)-based Therapeutics Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. GIVLAARI

6.2.2. Onpattro

6.2.3. OXLUMO

6.2.4. AMVUTTRA

6.2.5. Leqvio

6.3. Global Small Interfering RNA (siRNA)-based Therapeutics Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Small Interfering RNA (siRNA)-based Therapeutics Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Small Interfering RNA (siRNA)-based Therapeutics Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Small Interfering RNA (siRNA)-based Therapeutics Market Competition by Key Manufacturers

8.1. Global Small Interfering RNA (siRNA)-based Therapeutics Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Small Interfering RNA (siRNA)-based Therapeutics: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Alnylam Pharmaceuticals

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Novartis

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Sylentis

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Arrowhead Pharmaceuticals

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Silence Therapeutics

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Dicerna Pharmaceuticals

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Small Interfering RNA (siRNA)-based Therapeutics Market

Figure 4: Global Small Interfering RNA (siRNA)-based Therapeutics Market: Drivers

Figure 5: Global Small Interfering RNA (siRNA)-based Therapeutics Market: Challenges

Figure 6: Global Small Interfering RNA (siRNA)-based Therapeutics Market: Trends

Figure 7: Global Small Interfering RNA (siRNA)-based Therapeutics Market: Opportunity

Figure 8: Global Small Interfering RNA (siRNA)-based Therapeutics Market: Restraint

Figure 9: Global Small Interfering RNA (siRNA)-based Therapeutics Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Small Interfering RNA (siRNA)-based Therapeutics Market Value (USD Million) By Region

Figure 15: Global Small Interfering RNA (siRNA)-based Therapeutics Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Small Interfering RNA (siRNA)-based Therapeutics Market Value (USD Million) By Region

Figure 23: Global Small Interfering RNA (siRNA)-based Therapeutics Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

65 items

Table 1: Market Segmentation Analysis

Table 2: Global Small Interfering RNA (siRNA)-based Therapeutics Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Small Interfering RNA (siRNA)-based Therapeutics Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Small Interfering RNA (siRNA)-based Therapeutics Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Small Interfering RNA (siRNA)-based Therapeutics Market Value (USD Million) By Region

Table 10: Global Small Interfering RNA (siRNA)-based Therapeutics Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Small Interfering RNA (siRNA)-based Therapeutics Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Small Interfering RNA (siRNA)-based Therapeutics Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Small Interfering RNA (siRNA)-based Therapeutics Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Alnylam Pharmaceuticals Basic Information And Sales Area

Table 31: Alnylam Pharmaceuticals. Products Portfolio

Table 32: Novartis Basic Information And Sales Area

Table 33: Novartis. Products Portfolio

Table 34: Sylentis Basic Information And Sales Area

Table 35: Sylentis. Products Portfolio

Table 36: Arrowhead Pharmaceuticals Basic Information And Sales Area

Table 37: Arrowhead Pharmaceuticals. Products Portfolio

Table 38: Silence Therapeutics Basic Information And Sales Area

Table 39: Silence Therapeutics. Products Portfolio

Table 40: Dicerna Pharmaceuticals Basic Information And Sales Area

Table 41: Dicerna Pharmaceuticals. Products Portfolio

Table 42: Global Market Value (USD Million) (2025-2032) By Application

Table 43: Global Market Share (%) By Application (2032)

Table 44: Global Market Value (USD Million) (2025-2032) By Types

Table 45: Global Market Share (%) By Types (2032)

Table 46: Global Small Interfering RNA (siRNA)-based Therapeutics Market Value (USD Million) By Region

Table 47: Global Small Interfering RNA (siRNA)-based Therapeutics Market Share (%) By Region (2025-2032)

Table 48: North America Market Value (USD Million) (2025-2032) By Country

Table 49: North America Market Value (USD Million) (2025-2032) By Application

Table 50: North America Market Value (USD Million) (2025-2032) By Types

Table 51: Europe Market Value (USD Million) (2025-2032) By Country

Table 52: Europe Market Value (USD Million) (2025-2032) By Application

Table 53: Europe Market Value (USD Million) (2025-2032) By Types

Table 54: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 55: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 56: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 57: South America Market Value (USD Million) (2025-2032) By Country

Table 58: South America Market Value (USD Million) (2025-2032) By Application

Table 59: South America Market Value (USD Million) (2025-2032) By Types

Table 60: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 61: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 62: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 63: Research Programs/Design For This Report

Table 64: Key Data Information From Secondary Sources

Table 65: Key Data Information From Primary Sources

FAQs

1. What is the current Small Interfering RNA (siRNA)-based Therapeutics market size?

The Small Interfering RNA (siRNA)-based Therapeutics market size reached approximately USD 1.3 billion in 2023, driven by the approval of several first‑in‑class products and escalating investment in RNA‑focused pipelines across major biopharma firms worldwide and expanding payer reimbursement frameworks.

2. What is the growth forecast and CAGR for the next decade?

Analysts project the siRNA‑based Therapeutics market to expand at a compound annual growth rate of 12.4 % between 2024 and 2034, reaching roughly USD 4.8 billion by 2034. The robust forecast reflects accelerating clinical success and broader therapeutic indications.

3. Which key drivers are fueling market expansion?

Key drivers include the validation of RNA interference mechanisms, breakthrough delivery platforms such as lipid nanoparticles, rising prevalence of rare genetic disorders, and strong funding from both venture capital and large pharmaceutical partnerships targeting high‑unmet‑need disease areas.

4. What challenges could impede growth?

Challenges comprise scalable manufacturing of high‑purity siRNA, off‑target effects, limited long‑term safety data, reimbursement uncertainty for niche indications, and complex regulatory pathways that vary across jurisdictions, potentially slowing product launch timelines as well as intellectual‑property disputes over sequence patents.

5. Which regions are leading the siRNA therapeutics market?

North America dominates with the highest revenue share, driven by the United States’ extensive R&D ecosystem and favorable reimbursement policies. Europe follows, leveraging strong academic collaborations, while the Asia‑Pacific region is emerging rapidly, propelled by governmental biotech incentives.

6. Who are the top companies shaping the market?

Leading players include Alnylam Pharmaceuticals, which pioneered FDA‑approved siRNA drugs; Dicerna (now part of Novo Nordisk), Ionis Pharmaceuticals through its partnership with Akcea, and emerging biotech firms such as Arrowhead Pharmaceuticals and Silence Therapeutics, all investing heavily in pipeline diversification.

7. What future opportunities are emerging for siRNA therapeutics?

Future opportunities include expansion into oncology, cardiovascular disease, and central nervous system disorders, where tissue‑specific delivery advances promise efficacy. Additionally, combination regimens with gene‑editing tools and the development of oral or inhalable formulations could unlock new patient populations.

8. How is technology influencing the market’s trajectory?

Advanced nanocarriers, such as ionizable lipid nanoparticles and polymeric conjugates, improve cellular uptake and reduce immunogenicity, accelerating clinical translation. Machine‑learning‑guided sequence design also shortens discovery cycles, enabling rapid generation of high‑potency siRNA candidates across therapeutic areas.

9. What is the regulatory landscape for siRNA therapeutics?

Regulators such as the FDA and EMA have established dedicated guidance for oligonucleotide drugs, emphasizing chemistry, manufacturing, and control (CMC) rigor, as well as long‑term safety monitoring. Nonetheless, regional variations in data requirements and accelerated pathways create strategic planning challenges.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Small Interfering RNA (siRNA)-based Therapeutics Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	2.80 billion
Revenue forecast in 2033	13.30 billion
Growth rate	CAGR of 21.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Alnylam Pharmaceuticals; Novartis; Sylentis; Arrowhead Pharmaceuticals; Silence Therapeutics; Dicerna Pharmaceuticals
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options